Keywords

• Everolimus
• Everolimus Powder
• 159351-69-6

Quick Details

• ProName: Factory Supply Pharmaceutical API Ever...
• CasNo: 159351-69-6
• Molecular Formula: C53H83NO14
• Appearance: White crystal fine powder
• Application: Everolimus is a medication used as an ...
• DeliveryTime: 3-5 days
• PackAge: 1-5kg Bag 5-25kg Carton 25kg Drum
• Port: Shanghai,China
• ProductionCapacity: 500 Kilogram/Month
• Purity: 99%
• Storage: Cool Dry Place
• Transportation: 25KG/drum,or according to your require...
• LimitNum: 10 Gram
• Related Substances: ≥98%
• Residue on Ignition: ≤0.1%
• Heavy Metal: ≤0.1%
• Valid Period: 2 years
• Grade Standard: Pharmaceutical grade
• Test Method: HPLC UV
• Place of Origin: Xi‘an,China
• Purity: 99%
• State: Solid
• MF: C53H83NO14
• Storage: Cool Dry Place
• Shelf Life: 2 years
• Package: 1kg/Bag 25kg/Drum

Superiority

We promise our customer following items:

1.Support product customization:

We can provide OEM&ODM , Because we have a professional design team


2.Reasonable price:
We provide high quality products with competitive price in china,

3.Low moq:
No worry about the low moq, our moq is 1 gram or lower.

3.Good and efficient service,Fast Delivery
Fast respond save client's time, we promise to reply inquiry in 24 hours including holidays and send quotation sheet and other documents in 48 hours.

4.Super-good quality
We have strict quality control system .Good reputation in Market , And have the Third party test report is available


Pls contact us

If you have any further questions or need a sample,Please do not hesitate to contact us.

Xi'an Julong Bio-Tech Co., Ltd.

Details

                                                                                      Factory Supply Pharmaceutical API Everolimus CAS 159351-69-6

Everolimus, an orally adminstered rapamycin analog, has recently been approved by the FDA for treatment of renal cell carcinoma (RCC)
refractory to inhibitors of vascular endothelial growth factor (VEGF) receptor signaling. Everolimus significantly increased progression-free
survival (median PFS for the everolimus treated group was 4.0 months versus 1.9 months for the placebo group), although tumor regressions
were observed only infrequently. While the target for everolimus, (the serine/threonine kinase mTOR) is well established, the mechanism by
which this agent retards tumor growth is not well defined. Further, biomarkers that predict tumor sensitivity are still elusive. The mechanism
of action, preclinical antitumor activity, and clinical activity of everolimus against RCC are reviewed. 
Everolimus is a medication used as an immunosuppressant to prevent rejection of organ transplants and in the treatment of renal cell cancer and
other tumours. Much research has also been conducted on everolimus and other mTOR inhibitors as targeted therapy for use in a number of
cancers.

Everolimus is a macrolide derived from rapamycin (sc-3504) with immunosuppressant properties shown to inhibit cell proliferation induced by
growth factors. Macrolides belong to a group of antibiotics that bind to the 50S ribosomal subunit and inhibit protein synthesis. Studies indicate
that everolimus is a mTOR (FRAP) inhibitor that displays high affinity toward the intracellular receptor FKBP12. Additionally, the
Everolimus-FKBP12 complex decreases the activity of the S6K1 and 4EBP by binding to FRAP.

Julong Bio-Tech Co., Ltd. is located in Xi'an City, Shaanxi Province, China. It is a biotechnology enterprise engaged in the research, development,production and sales of
animal and plant extracts, cosmetics, pharmaceutical raw materials and intermediates. The company has complete experimental facilities. And advanced testing instruments
ensure the stability of product quality from all aspects. The company has a complete sales service system, the products are exported to countries all over the world, and have
won a good international reputation with excellent quality and excellent service.

The company has been adhering to the basic principles of "integrity, quality, service, and win-win" to serve customers, constantly strict requirements, set goals, and implement
win-win development.